{"id":"mdr-tb-treatment-regimen-who","safety":{"commonSideEffects":[{"rate":null,"effect":"Ototoxicity (hearing loss)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL2109410","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MDR-TB treatment regimens typically combine fluoroquinolones, injectable agents (aminoglycosides or polypeptides), and oral second-line drugs that inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication. The WHO-recommended regimen uses a longer intensive phase followed by a continuation phase to sterilize lesions and prevent relapse while managing resistance patterns. The multi-drug approach reduces the likelihood of selecting for additional resistance mutations.","oneSentence":"A standardized combination regimen of multiple anti-tuberculous drugs designed to overcome drug resistance in multidrug-resistant tuberculosis (MDR-TB) by targeting Mycobacterium tuberculosis through multiple mechanisms simultaneously.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:02.787Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multidrug-resistant tuberculosis (MDR-TB)"},{"name":"Tuberculosis resistant to isoniazid and rifampicin"}]},"trialDetails":[{"nctId":"NCT02354014","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-03","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":60},{"nctId":"NCT05633056","phase":"NA","title":"An Adaptive Randomized Controlled Trial","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-03-07","conditions":"Multi Drug Resistant Tuberculosis, HIV Infections","enrollment":360},{"nctId":"NCT03828201","phase":"PHASE2","title":"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB","status":"RECRUITING","sponsor":"Boston University","startDate":"2022-06-07","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":220},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT03896685","phase":"PHASE3","title":"Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2020-04-06","conditions":"Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary Tuberculoses","enrollment":323},{"nctId":"NCT02754765","phase":"PHASE3","title":"Evaluating Newly Approved Drugs for Multidrug-resistant TB","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2016-12","conditions":"Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses","enrollment":754},{"nctId":"NCT02619994","phase":"PHASE2","title":"Treatment Shortening of MDR-TB Using Existing and New Drugs","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":214},{"nctId":"NCT05278988","phase":"PHASE4","title":"A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB","status":"COMPLETED","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-04-01","conditions":"MDR-TB","enrollment":60},{"nctId":"NCT03867136","phase":"PHASE4","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2020-06-01","conditions":"Multidrug Resistant Tuberculosis","enrollment":354},{"nctId":"NCT02589782","phase":"PHASE2, PHASE3","title":"Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2017-01","conditions":"Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Pulmonary","enrollment":552},{"nctId":"NCT04207112","phase":"PHASE2, PHASE3","title":"Economic Evaluation of New MDR TB Regimens","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2020-10-20","conditions":"Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculoses","enrollment":73},{"nctId":"NCT06224036","phase":"PHASE2","title":"Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2023-10-31","conditions":"Drug-resistant Tuberculosis","enrollment":52},{"nctId":"NCT05926466","phase":"PHASE2","title":"BTZ-043 Dose Evaluation in Combination and Selection","status":"UNKNOWN","sponsor":"Michael Hoelscher","startDate":"2023-09-21","conditions":"Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis","enrollment":90},{"nctId":"NCT02409290","phase":"PHASE3","title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","startDate":"2016-03","conditions":"MDR-TB","enrollment":588},{"nctId":"NCT05493267","phase":"PHASE4","title":"A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-08-03","conditions":"MDR-TB, Immunotherapy","enrollment":30},{"nctId":"NCT03259269","phase":"","title":"Expand New Drugs for TB [endTB]","status":"COMPLETED","sponsor":"Partners in Health","startDate":"2015-04-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":2804},{"nctId":"NCT00685360","phase":"PHASE2","title":"A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-05-08","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis","enrollment":481},{"nctId":"NCT01131351","phase":"PHASE2","title":"Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-02-19","conditions":"Tuberculosis","enrollment":10},{"nctId":"NCT02573350","phase":"PHASE2","title":"A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-03-26","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":213},{"nctId":"NCT02454205","phase":"PHASE2, PHASE3","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2015-11-12","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis, Extensively-drug Resistant Tuberculosis","enrollment":154},{"nctId":"NCT01859923","phase":"PHASE2","title":"A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-07-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":37},{"nctId":"NCT03604848","phase":"NA","title":"NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-08-05","conditions":"Multidrug Resistant Tuberculosis","enrollment":488},{"nctId":"NCT02975570","phase":"PHASE3","title":"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin","status":"WITHDRAWN","sponsor":"Boston University","startDate":"2017-08","conditions":"Tuberculosis Multi Drug Resistant Active","enrollment":""},{"nctId":"NCT01509508","phase":"NA","title":"Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-03","conditions":"HIV Infection","enrollment":28153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":335,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["WHO Regimen"],"phase":"marketed","status":"active","brandName":"MDR-TB Treatment Regimen(WHO)","genericName":"MDR-TB Treatment Regimen(WHO)","companyName":"Shanghai Pulmonary Hospital, Shanghai, China","companyId":"shanghai-pulmonary-hospital-shanghai-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A standardized combination regimen of multiple anti-tuberculous drugs designed to overcome drug resistance in multidrug-resistant tuberculosis (MDR-TB) by targeting Mycobacterium tuberculosis through multiple mechanisms simultaneously. Used for Multidrug-resistant tuberculosis (MDR-TB), Tuberculosis resistant to isoniazid and rifampicin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}